SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Board appointment

12 Nov 2015 07:00

RNS Number : 4321F
Silence Therapeutics PLC
12 November 2015
 



 

 

 

Board appointment

12th November 2015

 

Silence Therapeutics plc

 

 

Silence Therapeutics plc, AIM: SLN ('Silence' or 'the Company'), a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, is pleased to announced the appointment of Alistair Gray as Non-Executive Director of the Company, with immediate effect. Alistair will also Chair the Audit Committee.

 

Alistair brings with him a wealth of consultancy and business experience. Having trained as an accountant, his early career was in senior management positions with Unilever and John Wood Group PLC. Alistair was a Director of Arthur Young (now Ernst and Young) Management Consultants and PA Consulting Group. Alistair founded Genesis Consulting and, most recently, Renaissance & Company, a strategic management consultancy working with clients across business and sport.

 

Alistair has served as Executive Chairman of the Winning Scotland Foundation and previously served as Chair of British Swimming and British Basketball, leading significant change in both sports. Alistair is currently Chairman of Edrington's Pension Trustees, responsible for management of a major private pension fund and also Chair of the trading division of John Hogg & Company. Alistair chaired the Audit and Remuneration committees of AorTech International PLC and Highland Distillers PLC, as well as the Pension Trustee Board. Alistair also served as a Fellow of the Institute of Directors and Institute of Consultants.

 

 

Stephen Parker Ph.D.  Non-Executive Chairman of Silence Therapeutics, said:

"We are delighted to welcome Alistair to the Board of Silence Therapeutics. His expertise in strategic leadership will be invaluable as we continue to expand our business and seek to deliver value to our shareholders."

 

 

Alistair William Gray, age 67, holds no shares in the Company. He holds or has held the following directorships within the last five years:

 

Current

Renaissance & Company Limited

 

Past

Winning Scotland Foundation (formerly The Scottish Institute of Sport Foundation)

British Swimming Limited

High Performance Swimming Limited

pmpgenesis Limited

Genesis Consulting Limited - dissolved

Genesis Research Limited - dissolved

Genesis Subsidiary Limited - dissolved

Genesis Red Limited - dissolved

 

Genesis Consulting Ltd, a company founded in 1992 by Alistair Gray was put into compulsory liquidation in February 2010. The associated companies were also dissolved.

 

Save as set out above, there are no further disclosures pursuant to paragraph (g) of Schedule 2 of the AIM Rules.

 

 

 

Enquiries:

 

Silence Therapeutics plc

Ali Mortazavi, Chief Executive Officer

Timothy Freeborn, Chief Financial Officer

Tel: +44 (0)20 3457 6900

 

Canaccord Genuity Limited (Nominated Adviser and Joint Broker)

Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel

Tel: +44 (0)20 7523 8350

 

 

Peel Hunt LLP (Joint Broker)

James Steel/Dr Tom Burt/Oliver Jackson

 

Tel: +44 (0)20 7418 8900

Media Enquiries:

FTI Consulting

Simon Conway/Brett Pollard/Stephanie Cuthbert

Tel: +44 (0) 20 3727 1000

 

 

 

 

Notes to Editors

 

About Silence Therapeutics plc

Our technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo.

We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics. This allows the development of therapeutics for diseases with high unmet medical need. In 2015 Silence announced interim results from a Phase 2a pancreatic cancer trial using its compound, Atu027, in combination with gemcitabine.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGMMMMMMKGKZZ
Date   Source Headline
16th Jan 20132:16 pmRNSHolding(s) in Company
14th Jan 20133:08 pmRNSReplacement - Exercise of warrants
14th Jan 20137:00 amRNSExercise of warrants
2nd Jan 20138:36 amRNSAppointment of Chief Medical Officer
31st Dec 201210:30 amRNSHolding(s) in Company
28th Dec 20127:00 amRNSTotal Voting Rights
6th Dec 20124:22 pmRNSHolding(s) in Company
3rd Dec 20123:12 pmRNSOption exercise
3rd Dec 20121:36 pmRNSHolding(s) in Company
3rd Dec 20121:34 pmRNSHolding(s) in Company
30th Nov 201212:52 pmRNSHolding(s) in Company
30th Nov 20128:05 amRNSHolding(s) in Company
30th Nov 20127:00 amRNSOption Exercise and TVR
28th Nov 20128:33 amRNSDirector/PDMR Shareholding
28th Nov 20127:49 amRNSSubscription and Conversion
21st Nov 20127:00 amRNSProposed Placing
5th Nov 201212:52 pmRNSAdviser Change of Name
5th Nov 201210:24 amPRNUS allows two key patents for Silence Therapeutics
19th Oct 20127:00 amPRNExercise of warrants
15th Oct 20127:01 amPRNExercise of warrants
15th Oct 20127:00 amPRNAppointment of finance director
25th Sep 20127:00 amPRNInterim Results for the Six Months Ended 30 June 2012
20th Sep 20122:59 pmPRNNotice of Results
18th Sep 20127:00 amPRNAppointment of Chief Medical Adviser
10th Sep 201211:12 amPRNTR-1: Notification of Major Interest in Shares
10th Sep 20127:00 amPRNSignificant Pre-clinical Data in Acute Lung Injury
4th Sep 201212:19 pmPRNTR-1: Notification of Major Interest in Shares
29th Aug 20124:40 pmRNSSecond Price Monitoring Extn
29th Aug 20124:35 pmRNSPrice Monitoring Extension
24th Aug 20122:41 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
22nd Aug 20127:00 amPRNCollaboration with MiReven Pty Ltd
20th Aug 20122:44 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
10th Aug 201212:20 pmPRNHolding(s) in Company
6th Aug 201212:21 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
3rd Aug 20125:35 pmPRNTR-1: Notification of Major Interest in Shares
2nd Aug 201212:12 pmPRNTR-1: Notification of Major Interest in Shares
2nd Aug 20129:00 amPRNAdmission of shares and Board update
31st Jul 201211:26 amPRNNotice of EGM
31st Jul 20127:00 amPRNResults of Open Offer
30th Jul 20125:35 pmPRNHolding(s) in Company
27th Jul 201212:12 pmPRNTR-1: Notification of Major Interest in Shares
24th Jul 20124:35 pmRNSPrice Monitoring Extension
13th Jul 20122:48 pmPRNReplacement - Subscription and Open Offer
12th Jul 20127:00 amPRNSubscription and Open Offer to Raise up to £5.7 million
10th Jul 201210:34 amPRNResponse to press speculation
22nd Jun 20121:35 pmPRNResult of Annual General Meeting
6th Jun 201212:00 pmPRNPhase I data for Atu027 and Potential Fundraising
17th May 20127:00 amPRNNew data from Phase I trial with Atu027
14th May 20127:00 amPRNPublication of 2011 Annual Report and Notice of AGM
3rd May 20127:00 amPRNSilence Therapeutics’ Partner extends agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.